Immunovant
IMVT
193 hedge funds and large institutions have $1.62B invested in Immunovant in 2025 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 91 increasing their positions, 44 reducing their positions, and 27 closing their positions.
107% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 44
30% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 27
17% more call options, than puts
Call options by funds: $34.5M | Put options by funds: $29.5M
4% more funds holding
Funds holding: 186 → 193 (+7)
1.19% more ownership
Funds ownership: 54.59% → 55.79% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
18% less capital invested
Capital invested by funds: $1.98B → $1.62B (-$365M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$86.7M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$78.4M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$73.2M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$17.9M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$16.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$24.4M |
| 2 |
BCM
Boxer Capital Management
San Diego,
California
|
-$20.4M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$14.2M |
| 4 |
RI
RTW Investments
New York
|
-$13.1M |
| 5 |
JP Morgan Chase
New York
|
-$10.5M |
IMVT Hedge Fund Activity: Q1 2025 in Review
193 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q1 2025, worth a combined $1.62B — down 18% from $1.98B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new IMVT positions and 27 closed out — a net gain of 8 holders — while 91 added to existing stakes and 44 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $86.7M. The largest seller was Franklin Resources, exiting entirely with an estimated $24.4M sold.
- 193 institutional investors held Immunovant (IMVT) as of Q1 2025, up from 186 in Q4 2024.
- Funds reported $1.62B of Immunovant stock for Q1 2025, down 18% quarter-over-quarter.
- 35 funds opened new Immunovant positions in Q1 2025 and 27 closed out, a net change of +8 holders.
- The largest Immunovant buyer in Q1 2025 was Fidelity Investments, an estimated $86.7M added.
- The largest Immunovant seller in Q1 2025 was Franklin Resources, an estimated $24.4M sold.
Based on aggregated 13F filings for Q1 2025.